Literature DB >> 19551841

Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells.

Nor Eddine Sounni1, Dmitri V Rozanov, Albert G Remacle, Vladislav S Golubkov, Agnes Noel, Alex Y Strongin.   

Abstract

Both invasion-promoting MT1-MMP and its physiological inhibitor TIMP-2 play a significant role in tumorigenesis and are identified in the most aggressive cancers. Despite its antiproteolytic effects in vitro, clinical data suggest that TIMP-2 expression is positively associated with tumor recurrence, thus emphasizing the wide-ranging role of TIMP-2 in malignancies. To shed light on this role of TIMP-2, we report that low concentrations of TIMP-2, by interacting with MT1-MMP (a specific membrane receptor of TIMP-2), induce the MEK/ERK signaling cascade in fibrosarcoma HT1080 cells which express MT1-MMP naturally. TIMP-2 binding with cell surface-associated MT1-MMP stimulates phosphorylation of MEK1/2, which is upstream of ERK1/2, and the ERK1/2 substrate p90RSK. Consistent with volumes of literature, we confirmed that the activation of ERK stimulated cell migration. Both the transcriptional silencing of MT1-MMP and the inhibition of MEK1/2 reversed the signaling effects of TIMP-2/MT1-MMP while the active site-targeting MMP inhibitor GM6001 did not. Our data suggest that both the interactions of TIMP-2 with MT1-MMP, which activate the pro-migratory ERK signaling cascade,and the conventional inhibition of MT1-MMP's catalytic activity by TIMP-2, play a role in the invasion-promoting function of MT1-MMP. The TIMP-2-induced stimulation of ERK signaling in cancer cells explains the direct, as opposed to the inverse, association of TIMP-2 expression with poor prognosis in cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19551841      PMCID: PMC2864114          DOI: 10.1002/ijc.24690

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  64 in total

1.  Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein.

Authors:  Ki-Kyung Jung; Xu-Wen Liu; Rosemarie Chirco; Rafael Fridman; Hyeong-Reh Choi Kim
Journal:  EMBO J       Date:  2006-08-17       Impact factor: 11.598

2.  O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP).

Authors:  Albert G Remacle; Alexei V Chekanov; Vladislav S Golubkov; Alexei Y Savinov; Dmitri V Rozanov; Alex Y Strongin
Journal:  J Biol Chem       Date:  2006-04-20       Impact factor: 5.157

Review 3.  Mislocalization and unconventional functions of cellular MMPs in cancer.

Authors:  Alex Y Strongin
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

4.  Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.

Authors:  M B Larsen; R W Stephens; N Brünner; H J Nielsen; L H Engelholm; I J Christensen; W G Stetler-Stevenson; G Høyer-Hansen
Journal:  Scand J Immunol       Date:  2005-05       Impact factor: 3.487

5.  An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature.

Authors:  Kaisa Lehti; Edward Allen; Henning Birkedal-Hansen; Kenn Holmbeck; Yasuhiro Miyake; Tae-Hwa Chun; Stephen J Weiss
Journal:  Genes Dev       Date:  2005-04-01       Impact factor: 11.361

6.  Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma.

Authors:  Fernanda Roca; Laura V Mauro; Ana Morandi; Fernando Bonadeo; Carlos Vaccaro; Guillermo Ojea Quintana; Sergio Specterman; Elisa Bal de Kier Joffé; María Guadalupe Pallotta; Lydia Inés Puricelli; José Lastiri
Journal:  J Surg Oncol       Date:  2006-02-01       Impact factor: 3.454

7.  Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.

Authors:  Zbigniew Pasieka; Henryk Stepien; Wojciech Czyz; Lech Pomorski; Krzysztof Kuzdak
Journal:  Endocr Regul       Date:  2004-06

8.  Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability.

Authors:  Vladislav S Golubkov; Sarah Boyd; Alexei Y Savinov; Alexei V Chekanov; Andrei L Osterman; Albert Remacle; Dmitri V Rozanov; Stephen J Doxsey; Alex Y Strongin
Journal:  J Biol Chem       Date:  2005-05-04       Impact factor: 5.157

9.  Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies.

Authors:  Oliver Galm; Hiromu Suzuki; Yoshimitsu Akiyama; Manel Esteller; Malcolm V Brock; Rainhardt Osieka; Stephen B Baylin; James G Herman
Journal:  Oncogene       Date:  2005-07-14       Impact factor: 9.867

10.  Characterization of the AB loop region of TIMP-2. Involvement in pro-MMP-2 activation.

Authors:  Magdalini Rapti; Vera Knaüper; Gillian Murphy; Richard A Williamson
Journal:  J Biol Chem       Date:  2006-06-15       Impact factor: 5.157

View more
  29 in total

1.  Potential relation of aberrant proteolysis of human protein tyrosine kinase 7 (PTK7) chuzhoi by membrane type 1 matrix metalloproteinase (MT1-MMP) to congenital defects.

Authors:  Vladislav S Golubkov; Alexander E Aleshin; Alex Y Strongin
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 2.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

3.  Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein-derived inhibitor.

Authors:  Hiroshi Hashimoto; Tomoka Takeuchi; Kyoko Komatsu; Kaoru Miyazaki; Mamoru Sato; Shouichi Higashi
Journal:  J Biol Chem       Date:  2011-08-03       Impact factor: 5.157

4.  Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.

Authors:  Albert G Remacle; Sergey A Shiryaev; Ilian A Radichev; Dmitri V Rozanov; Boguslaw Stec; Alex Y Strongin
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

5.  A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Authors:  Elisa Pin; Steven Stratton; Claudio Belluco; Lance Liotta; Ray Nagle; K Alex Hodge; Jianghong Deng; Ting Dong; Elisa Baldelli; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Mol Oncol       Date:  2016-10-14       Impact factor: 6.603

6.  Collagen regulation of let-7 in pancreatic cancer involves TGF-β1-mediated membrane type 1-matrix metalloproteinase expression.

Authors:  S Dangi-Garimella; M J Strouch; P J Grippo; D J Bentrem; H G Munshi
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

7.  Stable expression of α1-antitrypsin Portland in MDA-MB-231 cells increased MT1-MMP and MMP-9 levels, but reduced tumour progression.

Authors:  J A Willson; C A Muir; C L Evered; M A Cepeda; S Damjanovski
Journal:  J Cell Commun Signal       Date:  2017-08-29       Impact factor: 5.782

8.  Inhibition of MT1-MMP proteolytic function and ERK1/2 signalling influences cell migration and invasion through changes in MMP-2 and MMP-9 levels.

Authors:  Mario A Cepeda; Caitlin L Evered; Jacob J H Pelling; Sashko Damjanovski
Journal:  J Cell Commun Signal       Date:  2017-01-09       Impact factor: 5.782

9.  Insights into ectodomain shedding and processing of protein-tyrosine pseudokinase 7 (PTK7).

Authors:  Vladislav S Golubkov; Alex Y Strongin
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

10.  Immunoexpression of metalloproteinases 2 and 14 and TIMP-2 inhibitor in main types of primary gastric carcinomas and lymph node metastasis.

Authors:  Daniel Cordeiro Gurgel; José Telmo Valença-Junior; Conceição Aparecida Dornelas; Renato Braga Vieira; João Tarcisio Alves Maia-Filho; Roberto Cesar Pereira Lima-Junior; Ronaldo Albuquerque Ribeiro; Paulo Roberto Carvalho Almeida
Journal:  Pathol Oncol Res       Date:  2014-05-07       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.